SiPhox Health vs Warby Parker
Side-by-side comparison of AI visibility scores, market position, and capabilities
MIT-founded home blood testing company measuring 17 biomarkers via mail-in kits; Khosla-backed developing photonic chip for instant at-home results competing with Everlywell.
About
SiPhox Health is a home blood testing company founded by MIT scientists that provides mail-in blood test kits measuring 17 key biomarkers — inflammation markers (CRP, homocysteine), cardiovascular health (LDL, HDL, triglycerides, ApoB), metabolic health (HbA1c, glucose, insulin), and hormone levels (testosterone, DHEA, cortisol) — with results delivered within days and integrated with an app for trend tracking and health guidance. Founded in 2020 by Diedrik Vermeulen and Michael Dubrovsky, SiPhox Health is backed by Khosla Ventures, Intel Capital, and Y Combinator.\n\nSiPhox's current product uses at-home finger-prick blood collection with mail-in testing — customers order a $95 kit, collect a small blood sample at home, and mail it to SiPhox's CLIA-certified lab for analysis. The $16/month membership provides regular testing on a quarterly or customizable schedule, enabling biomarker trend monitoring over time rather than single point-in-time snapshots. The underlying technology vision is a photonic chip (silicon photonics-based biosensor) that would enable instant at-home blood analysis without lab processing, with FDA clearance targeted for 2026.\n\nIn 2025, SiPhox Health competes in the home diagnostics and consumer health testing market with Everlywell (the leading at-home test kit brand), Function Health (comprehensive blood panel membership), InsideTracker, and traditional lab companies (LabCorp, Quest Diagnostics) for consumer blood testing. The longevity and proactive health monitoring movement has driven demand for comprehensive biomarker testing beyond what annual physicals provide. The potential photonic chip breakthrough would represent a significant technological leap — enabling truly point-of-care diagnostics without lab infrastructure. The 2025 strategy focuses on growing the biomarker panel subscription business, advancing the photonic chip development toward FDA clearance, and building clinical evidence for the personalized health intervention recommendations.
NYSE-listed (WRBY) DTC eyewear brand with $669M revenue and 240+ stores; vertical integration enabling $95-195 glasses competing with LensCrafters while pursuing profitability path after 2021 IPO.
About
Warby Parker is a New York-based direct-to-consumer eyewear company that disrupted the traditional optical retail industry by designing, manufacturing, and selling prescription glasses and sunglasses directly to consumers at $95-$195 price points — compared to $300-500 at traditional optical retailers that added brand markups, optician markups, and optical shop overhead. Listed on NYSE (NYSE: WRBY), Warby Parker generated $669 million in net revenue in fiscal year 2023 and operates 240+ retail stores across the US and Canada alongside its e-commerce and home try-on program.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.